Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies

Journal of Medical Microbiology

Volumn 64, Issue 7, 2015, Pages 676-681

  Woerther, Paul Louis ^a   Micol, Jean Baptiste ^a   Angebault, Cécile ^b,c   Pasquier, Florence ^a   Pilorge, Sylvain ^a   Bourhis, Jean Henri ^a   de Botton, Stéphane ^a   Gachot, Bertrand ^a   Chachaty, Elisabeth ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; COLISTIN; QUINOLONE DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM CARRIER; BACTERIUM ISOLATION; CONTROLLED STUDY; ENTEROBACTERIACEAE; FECES ANALYSIS; FECES CULTURE; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ADOLESCENT; COMPLICATION; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; FECES; GENETICS; HEMATOLOGIC DISEASE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FECES; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84938401150     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.000078     Document Type: Article

References (20)

1. Arnan, M., Gudiol, C., Calatayud, L., Lińares, J., Dominguez, M. A., Batlle, M., Ribera, J. M., Carratalá, J. & Gudiol, F. (2011). Risk factors for, and clinical relevance of, faecal extended-spectrum blactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 30, 355–360.
2. Averbuch, D., Orasch, C., Cordonnier, C., Livermore, D. M., Mikulska, M., Viscoli, C., Gyssens, I. C., Kern, W. V., Klyasova, G. & other authors (2013). European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98, 1826–1835.
3. Bow, E. J. (2005). Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect 11 (Suppl 5), 24–29.
4. Bow, E. J. (2013). There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. J Antimicrob Chemother 68, 492–495.
5. Cantón, R., Akóva, M., Carmeli, Y., Giske, C. G., Glupczynski, Y., Gniadkowski, M., Livermore, D. M., Miriagou, V., Naas, T. & other authors (2012). Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18, 413–431.
6. Cornejo-Juárez, P., Pérez-Jiménez, C., Silva-Sánchez, J., Velázquez-Acosta, C., Gonzá lez-Lara, F., Reyna-Flores, F., Sánchez-Pérez, A. & Volkow-Fernández, P. (2012). Molecular analysis and risk factors for Escherichia coli producing extendedspectrum b-lactamase bloodstream infection in hematological malignancies. PLoS One 7, e35780.
7. Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I. II, Rolston, K. V., Young, J. A. & other authors (2011). Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52, 427–431.
8. Friedman, C. R. & Whitney, C. G. (2008). It’s time for a change in practice: reducing antibiotic use can alter antibiotic resistance. J Infect Dis 197, 1082–1083.
9. Gudiol, C., Calatayud, L., Garcia-Vidal, C., Lora-Tamayo, J., Cisnal, M., Duarte, R., Arnan, M., Marin, M., Carratalä, J. & Gudiol, F. (2010). Bacteraemia due to extended-spectrum beta-lactamaseproducing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65, 333–341.
10. Kim, S. H., Kwon, J. C., Choi, S. M., Lee, D. G., Park, S. H., Choi, J. H., Yoo, J. H., Cho, B. S., Eom, K. S. & other authors (2013). Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum blactamase production and its impact on outcome. Ann Hematol 92, 533–541.
11. Kwon, J. C., Kim, S. H., Choi, J. K., Cho, S. Y., Park, Y. J., Park, S. H., Choi, S. M., Lee, D. G., Choi, J. H. & Yoo, J. H. (2013). Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the catholic blood and marrow transplantation center. Infect Chemother 45, 51–61.
12. Liss, B. J., Vehreschild, J. J., Cornely, O. A., Hallek, M., Fätkenheuer, G., Wisplinghoff, H., Seifert, H. & Vehreschild, M. J. (2012). Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40, 613–619.
13. Micol, J. B., Chahine, C., Woerther, P. L., Ghez, D., Netzer, F., Dufour, C., Merad, M., Blot, F., Chachaty, E. & other authors (2014). Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical? Clin Microbiol Infect 20, O453–O455.
14. Ortega, M., Marco, F., Soriano, A., Almela, M., Martínez, J. A., Muńoz, A. & Mensa, J. (2009). Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 63, 568–574.
15. Pizzo, P. A., Robichaud, K. J., Gill, F. A. & Witebsky, F. G. (1982). Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72, 101–111.
16. Tancrède, C. H. & Andremont, A. O. (1985). Bacterial translocation and Gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 152, 99–103.
17. Tumbarello, M., Sali, M., Trecarichi, E. M., Leone, F., Rossi, M., Fiori, B., De Pascale, G., D’Inzeo, T. & Sanguinetti, M. (2008). Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 52, 3244–3252.
18. Tumbarello, M., Trecarichi, E. M., Bassetti, M., De Rosa, F. G., Spanu, T., Di Meco, E., Losito, A. R., Parisini, A., Pagani, N. & Cauda, R. (2011). Identifying patients harboring extended-spectrum-betalactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 55, 3485–3490.
19. Walsh, T. R. & Toleman, M. A. (2012). The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. J Antimicrob Chemother 67, 1–3.
20. Woerther, P. L., Burdet, C., Chachaty, E. & Andremont, A. (2013). Trends in human fecal carriage of extended-spectrum b-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev 26, 744–758.